At Lung Innovations Network, we strive to provide our patients with the most advanced treatments to improve quality of life and slow disease progression.  Our Providers have the most up to date knowledge on disease processes and have the capability of prescribing agents for allergic and eosinophilic pulmonary conditions such as asthma and COPD, interstitial lung disease, pulmonary arterial hypertension, and alpha 1 antitrypsin deficiency. Our treatment capabilities also include:

​

• Biologic agents for allergic and eosinophilic Pulmonary and interstitial lung diseases 

• Pulmonary vasodilation  

• Treatment options include Oral and injectable agents